UPC CFI 124/2024
Mar 19, 2024·EP3167888 Unitary patent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Case details
- StatusCase ClosedActionProvisional measuresCategoryProvisional measures
- Parties
- Respondents
- Amgen Technology (Ireland) Unlimited CompanyOperating co.
Representatives- Tilman Mueller-Stoy-Bardehle Pagenberg
- Division
- Hamburg LD
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- English
- First decided
- Jun 26, 2024
- EPO Opposition
- Samsung Bioepis NL B.V.Withdrawn2024-05-02
- Amgen Technology (Ireland) Unlimited CompanyWithdrawn2024-10-28
- Salute HC Ilaç Pazarlama A.S.Admissible2025-01-31
| Preliminary injunction granted | Median days to first decision | |
|---|---|---|
| All UPC | 54% (38/70) | 124 |
| Hamburg LD | Locked | Locked |
| Judge Sabine Klepsch | Locked | Locked |
| Judge Alima Zana | Locked | Locked |
| Judge Stefan Schilling | Locked | Locked |
| Judge Rudi Goedeweeck | Locked | Locked |
At the UPC: AstraZeneca Group (13 cases)·Amgen Group (19 cases)
This dispute contains 2 other proceedings
6 other defendants litigating the same or a related patent
UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC CFI 642/2024·UPC CoA 402/2024 and 1 more
Start a free trial to see how each one ended.
More cases: Hamburg LD·2024
- 2024-06-26Application for provisional measuresPublic
Summary: The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against multiple Amgen entities based on EP 3 167 888, holding that while infringement could be established the court lacked sufficient certainty of patent validity given the EPO's repeated rejection of sequence correction attempts for SEQ ID NO:4.
Show the legal issues (3)
- preliminary injunction standard Art. 62(2) UPCA
- validity certainty requirement Art. 62(4) UPCA
- SEQ ID NO:4 disclosure and correction history
| Document title | Date | Public |
|---|---|---|
| Case closed | 2025-12-05 | Not public |
| Order | 2025-12-05 | Not public |
| Order | 2025-12-05 | Not public |
| Cover sheet | 2025-12-03 | Not public |
| Other document Defendant | 2025-12-03 | Not public |
| Other document Defendant | 2025-12-03 | Not public |
| Receipt | 2025-12-03 | Not public |
| Order | 2025-12-02 | Not public |
| Order | 2025-12-02 | Not public |
| Cover sheet | 2025-11-26 | Not public |
Alexion Pharmaceuticals applied for a preliminary injunction at the Hamburg Local Division against nine Amgen entities across multiple European countries regarding EP 3 167 888 B1 (eculizumab/paroxysmal nocturnal haemoglobinuria). Identical reasoning to UPC_CFI_123/2024: the court found infringement could be established but denied the measure because the TBA's consistent rejection of SEQ ID NO:4 correction attempts created insufficient certainty of patent validity; value of dispute was EUR 100,000,000.
Sufficient certainty of patent validity is required before granting provisional measures, assessed in light of likely EPO outcome
RespondentLegal basis: Art. 62(4) UPCA; R. 211.2 RoPNote: Same legal reasoning as UPC_CFI_123/2024: the Hamburg court declined the PI because TBA history created serious doubt about EP 3 167 888 B1's validity.
Preliminary injunction against Amgen entities based on EP 3 167 888 B1
ClaimantLegal basis: Art. 62(4) UPCA; R. 211.2 RoPReason: Although infringement could be established, the court lacked sufficient certainty of patent validity given the TBA's consistent rejection of all attempts to correct SEQ ID NO:4 and claim sets directed to eculizumab across the EP 888 patent family.
Browse other cases on this principle.
Identical to UPC_CFI_123/2024: the court construed EP 3 167 888 claims but found it could not be sufficiently certain of validity given the TBA's repeated holdings that SEQ ID NO:4 includes the signal peptide sequence and its refusal to allow correction.